Table 2.

Baseline characteristics and measurement of SBV pre-intervention and post-intervention

Study Title	Publication Year	Number of Participants (N)	Primary Outcome	Age (years)	BMI (kg/m2)	LVEF (%)	Intervention	Resting SBV Pre-intervention (ml)	Resting SBV Post-intervention (ml)	Pre-intervention SBV at peak load	Post-Intervention SBV at  Peak Load (ml)
Kaye et al. (23)	2020	10	Left ventricular end-systolic, end-diastolic pressure–volume relations, stressed blood volume, heart rate, and arterial mechanics	68 ± 2	31 ± 1	64 ± 2	Milrinone	1539	1066	-	-
Brener et al. (28)	2021	35	Mean pulmonary capillary wedge pressure at rest and during exercise	68 ± 9	34 ± 8	58 ± 8	Levosimendan	2750	2449*	-	-
Fudim et al.(10)	2021	14	Exercise capacity measured by peak oxygen uptake, mean pulmonary arterial pressure, and pulmonary capillary wedge pressure	58 ± 13	31 ± 16	21 ± 12	Splanchnic nerve blockade	2,664 ± 488	2,132 ± 570	3,243 ± 352	2662 ± 656
Okamoto et al. (26)	2021	85	Effect of SL NTG for increasing splanchnic capacitance and compliance	37 ± 44	31 ± 38	-	Nitroglycerin	100 ± 1.81 *	104.6 ± 8.81*	-	-
Omar et al. (30)	2021	35	Change in estimated SBV after 12 weeks of empagliflozin treatment	59 ± 8	29 ± 6	-	Empaglifozin	1697 ± 312	1601 ± 337	3269 ± 486	3105 ± 509

Values are mean ± SD or n or cm H20/ relative splanchnic volume*.

SBV indicates stressed blood volume; BMI indicates body mass index; LVEF indicates left ventricular ejection fraction; SL NTG indicates sublingual nitroglycerin.